Aprepitant and Granisetron for the Prophylaxis of Radiotherapy-Induced Nausea and Vomiting after Moderately Emetogenic Radiotherapy for Bone Metastases: A Prospective Pilot Study

Dennis, Kristopher; DeAngelis, Carlo; Jon, Florencia; Lauzon, Natalie; Pasetka, Mark; Holden, Lori; Barnes, Elizabeth; Danjoux, Cyril; Sahgal, Arjun; Tsao, May; Chow, Edward

doi:10.3747/co.21.2051

Cited by 15 publications

(6 citation statements)

References 21 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…However, to the best of our knowledge, no investigation in either vomit-competent animals or humans has been conducted to characterize the validity of the two phases of RINV in a dose- and time-dependent fashion. In fact, the duration of acute RINV phase has arbitrarily been defined as the first day of radiotherapy to the first day after radiation exposure, while the second phase is regarded as nausea and vomiting occurring from day 2 up to 10 days posttherapy [ 160 , 161 ]. Vomiting can be initiated by release of emetic mediators when radiation therapy beams is directed toward the: (i) brainstem area or (ii) gastrointestinal portion of the body trunk, where splanchnic/vagal afferents release the aforementioned emetic neurotransmitter involved in CINV [ 162 ].…”

Section: Physiological Mechanisms Of Emesis and Clinical Uses Of Antiemeticsmentioning

confidence: 99%

Mechanisms of Nausea and Vomiting: Current Knowledge and Recent Advances in Intracellular Emetic Signaling Systems

Zhong

Shahbaz

Teskey

et al. 2021

IJMS

116

View full text Add to dashboard Cite

Nausea and vomiting are common gastrointestinal complaints that can be triggered by diverse emetic stimuli through central and/or peripheral nervous systems. Both nausea and vomiting are considered as defense mechanisms when threatening toxins/drugs/bacteria/viruses/fungi enter the body either via the enteral (e.g., the gastrointestinal tract) or parenteral routes, including the blood, skin, and respiratory systems. While vomiting is the act of forceful removal of gastrointestinal contents, nausea is believed to be a subjective sensation that is more difficult to study in nonhuman species. In this review, the authors discuss the anatomical structures, neurotransmitters/mediators, and corresponding receptors, as well as intracellular emetic signaling pathways involved in the processes of nausea and vomiting in diverse animal models as well as humans. While blockade of emetic receptors in the prevention of vomiting is fairly well understood, the potential of new classes of antiemetics altering postreceptor signal transduction mechanisms is currently evolving, which is also reviewed. Finally, future directions within the field will be discussed in terms of important questions that remain to be resolved and advances in technology that may help provide potential answers.

show abstract

Section: Physiological Mechanisms Of Emesis and Clinical Uses Of Antiemeticsmentioning

confidence: 99%

Mechanisms of Nausea and Vomiting: Current Knowledge and Recent Advances in Intracellular Emetic Signaling Systems

Zhong

Shahbaz

Teskey

et al. 2021

IJMS

116

View full text Add to dashboard Cite

show abstract

“…More patients on the emetic prophylaxis containing tachykinin NK-1 receptor antagonists reached a complete response [ 25 ]. Dennis et al showed the combination of granisetron and aprepitant being safe and efficacious for the prophylaxis of RINV in single and multiple fraction moderately emetogenic radiotherapy for thoracolumbar bone metastases evaluating only a very small sample size with 19 patients [ 26 ].…”

Section: Prevention and Treatmentmentioning

confidence: 99%

Prophylactic Management of Radiation-Induced Nausea and Vomiting

Feyer

Jahn

Jordan

2015

BioMed Research International

View full text Add to dashboard Cite

The incidence of nausea and vomiting after radiotherapy is often underestimated by physicians, though some 50–80% of patients may experience these symptoms. The occurrence of radiotherapy-induced nausea and vomiting (RINV) will depend on radiotherapy-related factors, such as the site of irradiation, the dosing, fractionation, irradiated volume, and radiotherapy techniques. Patients should receive antiemetic prophylaxis as suggested by the international antiemetic guidelines based upon a risk assessment, taking especially into account the affected anatomic region and the planned radiotherapy regimen. In this field the international guidelines from the Multinational Association of Supportive Care in Cancer (MASCC)/European Society of Medical Oncology (ESMO) and the American Society of Clinical Oncology (ASCO) guidelines as well as the National Comprehensive Cancer Network (NCCN) are widely endorsed. The emetogenicity of radiotherapy regimens and recommendations for the appropriate use of antiemetics including 5-hydroxytryptamine (5-HT3) receptor antagonists, steroids, and other antiemetics will be reviewed in regard to the applied radiotherapy or radiochemotherapy regimen.

show abstract

“…[11][12][13] Few reported clinical trials have provided efective prevention or treatment recommendations for RINV. [14][15][16] Concurrent chemotherapy radiotherapy is commonly used for locally advanced head and neck cancers 17 and locally advanced esophageal cancers. 18 Tere are no known prospective phase 3 clinical trials for the prevention of chemotherapy radiotherapy-induced nausea and vomiting for these malignancies.…”

mentioning

confidence: 99%

Olanzapine versus fosaprepitant for the prevention of concurrent chemotherapy radiotherapy-induced nausea and vomiting

Navari¹,

Nagy²,

Le‐Rademacher³

et al. 2016

J Community Support Oncol

View full text Add to dashboard Cite

Aprepitant and Granisetron for the Prophylaxis of Radiotherapy-Induced Nausea and Vomiting after Moderately Emetogenic Radiotherapy for Bone Metastases: A Prospective Pilot Study

Abstract: ConclusionsThe combination of aprepitant and granisetron was safe and efficacious for the prophylaxis of rinv after both single-and multiple-fraction moderately emetogenic radiotherapy for thoracolumbar bone metastases. Our results require confirmation in a larger population.

Cited by 15 publications

References 21 publications

Mechanisms of Nausea and Vomiting: Current Knowledge and Recent Advances in Intracellular Emetic Signaling Systems

Mechanisms of Nausea and Vomiting: Current Knowledge and Recent Advances in Intracellular Emetic Signaling Systems

Prophylactic Management of Radiation-Induced Nausea and Vomiting

Olanzapine versus fosaprepitant for the prevention of concurrent chemotherapy radiotherapy-induced nausea and vomiting

Contact Info

Product

Resources

About